How a Swiss Startup's New Device Could Change the Future of Prenatal Surgery

Jan de Vries · 2026-08-31

Here's some interesting news from the European MedTech scene. A Swiss startup just landed a major funding boost, and it's all about tackling one of the most delicate challenges in modern medicine. Zurich-based KOVE Medical has secured $1.8 million in a recent funding round. That capital is specifically aimed at developing an implantable device designed to reduce a critical risk associated with fetal surgery: preterm birth. This fresh funding will help the company move closer to First-in-Human clinical studies, which is a huge milestone. The round was supported entirely by a syndicate of angel investors. It's a vote of confidence in a very specialized field. CEO and co-founder Yannick Devaud captured the sentiment perfectly, saying, "Thanks to the team and our strong Angel investors team. Let's go tackle health issues at the beginning of life!" ### A Wave of European MedTech Investment This deal didn't happen in a vacuum. It's part of a significant trend of investment flowing into European medical-device companies in 2026. Think about it—this year has already seen some massive rounds announced. To give you some context, here's a quick look at other notable deals: - FineHeart, a French cardiac-device developer, raised a staggering $89 million. - Ireland's Neurent Medical secured $66.5 million for minimally invasive treatments. - Dutch-US company Xeltis got $21.8 million for vascular implants. - Belgian surgical-imaging startup SamanTree Medical closed a $21.3 million round. Even within Switzerland, Lausanne-based Xsensio raised $6.4 million for wearable biochemical sensors. When you add it all up, we're talking about roughly $206 million in disclosed MedTech financing in Europe this year alone. KOVE's funding is a key piece of that puzzle, proving investor appetite for innovative, life-beginning technologies. ### The Problem KOVE Is Trying to Solve So, what's the big deal? KOVE Medical, founded in 2020 by Yannick Devaud and Kurt Ruffieux from research at the University of Zurich, is focused on a procedure called fetoscopy. This is a minimally invasive surgery that lets doctors treat serious conditions in babies before they're even born. We're talking about conditions like spina bifida, twin-to-twin transfusion syndrome, and congenital diaphragmatic hernia. It's pretty amazing technology. But here's the catch. To perform these procedures, surgeons have to pass instruments through the uterine wall and the amniotic sac. That creates an opening. That opening can weaken the fetal membrane, sometimes leading to leaks of amniotic fluid. In the worst cases, it causes the membrane to rupture prematurely, which directly leads to preterm birth. It's a major limitation that holds back the wider use of these potentially life-changing prenatal surgeries. ### A Simple, Five-Minute Fix? KOVE's proposed solution is elegantly simple in concept. They're developing a small implant designed to close that surgical opening right after the fetal procedure is finished. The device is placed from inside the amniotic cavity to stabilize the membrane at the exact puncture site. The clever part? The company says it's compatible with the entry ports surgeons are already using. That means no extra puncture is needed just to seal things up. They also claim the entire placement process takes less than five minutes. If it works as intended, this device could give surgeons a reliable way to secure the amniotic membrane, potentially reducing a key risk and allowing for more complex interventions to be developed. It's one of those ideas that makes you think, "Why hasn't this been done before?" The long-term goal is clear: to make fetal surgery safer and more accessible, giving more families hope for a healthier start to life.